Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Post-Essential Thrombocythemia Myelofibrosis (Post-ET-MF)”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)UnknownNCT04485260
What this trial is testing

An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post ET-MF) Who Have a Suboptimal Response to Ruxolitinib

Who this might be right for
Myelofibrosis
Kartos Therapeutics, Inc. 36
Testing effectiveness (Phase 2)Ended earlyNCT02730884
What this trial is testing

Single-Arm Study of the Efficacy and Safety of Oral Rigosertib in Patients With Myelofibrosis (MF) and Anemia

Who this might be right for
LeukemiaMyelofibrosisAnemia+1 more
M.D. Anderson Cancer Center 3
Large-scale testing (Phase 3)Study completedNCT01969838
What this trial is testing

Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis

Who this might be right for
Primary MyelofibrosisPost-Polycythemia Vera MyelofibrosisPost-Essential Thrombocythemia Myelofibrosis
Sierra Oncology LLC - a GSK company 432
Early research (Phase 1)Ended earlyNCT03373877
What this trial is testing

Evaluation of Ruxolitinib in Combination With PU-H71 for Treatment of Myelofibrosis

Who this might be right for
MyelofibrosisPrimary MyelofibrosisPost-polycythemia Vera Myelofibrosis+1 more
Samus Therapeutics, Inc. 4
Testing effectiveness (Phase 2)Study completedNCT01200498
What this trial is testing

Study of SB939 in Subjects With Myelofibrosis

Who this might be right for
Myeloproliferative Disorders
M.D. Anderson Cancer Center 23
Testing effectiveness (Phase 2)Study completedNCT01423851
What this trial is testing

Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF

Who this might be right for
Primary MyelofibrosisPost-Polycythemia Vera MyelofibrosisPost-Essential Thrombocythemia Myelofibrosis
NS Pharma, Inc. 77
Early research (Phase 1)Ended earlyNCT01291784
What this trial is testing

Anti-TGF-beta Therapy in Patients With Myelofibrosis

Who this might be right for
MyelofibrosisPrimary MyelofibrosisPolycythemia Vera, Post-Polycythemic Myelofibrosis Phase+1 more
John Mascarenhas 3
Testing effectiveness (Phase 2)Study completedNCT01732445
What this trial is testing

Ruxolitinib Phosphate and Danazol in Treating Anemia in Patients With Myelofibrosis

Who this might be right for
AnemiaPrimary MyelofibrosisSecondary Myelofibrosis
Mayo Clinic 14
Not applicableLooking for participantsNCT07362225
What this trial is testing

MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)

Who this might be right for
Polycythemia VeraET (Essential Thrombocythemia)Polycythemia Vera (PV)+52 more
MPN Research Foundation 5,000
Testing effectiveness (Phase 2)WithdrawnNCT04054245
What this trial is testing

PAT-1251 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis

Who this might be right for
Myelofibrosis Transformation in Essential ThrombocythemiaPolycythemia Vera, Post-Polycythemic Myelofibrosis PhasePrimary Myelofibrosis
M.D. Anderson Cancer Center
Early research (Phase 1)Study completedNCT03895112
What this trial is testing

MPN-RC 118 AVID200 in Myelofibrosis

Who this might be right for
Primary MyelofibrosisPost-essential Thrombocythemia MyelofibrosisPost-polycythemia Vera Myelofibrosis+2 more
John Mascarenhas 21
Testing effectiveness (Phase 2)Study completedNCT02098161
What this trial is testing

LCL161 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis

Who this might be right for
Polycythemia Vera, Post-Polycythemic Myelofibrosis PhasePrimary MyelofibrosisSecondary Myelofibrosis
M.D. Anderson Cancer Center 50
Large-scale testing (Phase 3)Study completedNCT03952039
What this trial is testing

An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib

Who this might be right for
Primary MyelofibrosisPost-Polycythemia VeraMyelofibrosis
Celgene 202
Testing effectiveness (Phase 2)Looking for participantsNCT06327100
What this trial is testing

Open Label Phase 1/2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)

Who this might be right for
Primary MyelofibrosisPost-polycythemia Vera MyelofibrosisPost-Essential Thrombocytosis Myelofibrosis
M.D. Anderson Cancer Center 33
Testing effectiveness (Phase 2)Study completedNCT01981850
What this trial is testing

RO7490677 In Participants With Myelofibrosis

Who this might be right for
Primary MyelofibrosisPolycythemia VeraPost-Essential Thrombocythemia Myelofibrosis
Hoffmann-La Roche 125
Testing effectiveness (Phase 2)Study completedNCT00946270
What this trial is testing

Pomalidomide for Myelofibrosis Patients

Who this might be right for
Polycythemia VeraThrombocythemia
M.D. Anderson Cancer Center 70
Early research (Phase 1)UnknownNCT05279001
What this trial is testing

A Safety and Tolerability Study of Jaktinib

Who this might be right for
Myelofibrosis
Suzhou Zelgen Biopharmaceuticals Co.,Ltd 26
Testing effectiveness (Phase 2)Looking for participantsNCT05280509
What this trial is testing

Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib

Who this might be right for
MyelofibrosisPrimary MyelofibrosisPost-PV MF+1 more
Telios Pharma, Inc. 70
Large-scale testing (Phase 3)Ended earlyNCT03755518
What this trial is testing

A Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib

Who this might be right for
Primary MyelofibrosisPost-Polycythemia Vera MyelofibrosisMyelofibrosis+1 more
Celgene 38
Testing effectiveness (Phase 2)Study completedNCT01392443
What this trial is testing

Asian Phase II Study of INC424 in Patients With Primary Myelofibrosis (MF), Post-PV MF or Post-ET MF

Who this might be right for
Primary Myelofibrosis (MF)Post-Polycythemia Vera (PV) MFPost-Essential Thrombocythemia (ET) MF
Novartis Pharmaceuticals 120
Next Page